UPTIDE
← Research Database/← NAD+/Metabolic Research

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.

Mixed2021clinical trial (randomized, prediabetic postmenopausal women)NAD+ →

Yoshino M, Yoshino J, Kayser BD, et al. · Science

PubMed · PMID 33888596 DOI 10.1126/science.abe9985 PMC · PMC8550608 Search PubMed Google Scholar
Abstract / Summary

Ten weeks of oral nicotinamide mononucleotide (NMN) increased skeletal-muscle insulin sensitivity and altered insulin-signalling protein expression in prediabetic postmenopausal women, the first randomized clinical demonstration of a metabolic effect of NMN supplementation in humans.

Methods

Investigated as a clinical trial (randomized, prediabetic postmenopausal women) in the field of metabolic research. The study design follows the methodology described in the published manuscript indexed under the identifiers listed above. Full methodological detail is available in the source publication via the PubMed or DOI link.

Results

Ten weeks of oral nicotinamide mononucleotide (NMN) increased skeletal-muscle insulin sensitivity and altered insulin-signalling protein expression in prediabetic postmenopausal women, the first randomized clinical demonstration of a metabolic effect of NMN supplementation in humans.

Limitations

Small sample (n≈25), single dose, short duration; does not establish long-term safety or efficacy for ageing or diabetes prevention.

External links